Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment

Chungen Li,Xiaowei Yang,Yuan Luo,Huan Liu,Xi Zhong,Xia Zhou,Ting Zeng,Lei Tao,Yue Zhou,Kun Gou,Xinyu Yang,Xiaocong Liu,Qiang Chen,Yinglan Zhao,Youfu Luo
DOI: https://doi.org/10.1021/acs.jmedchem.1c01711
IF: 8.039
2021-12-14
Journal of Medicinal Chemistry
Abstract:Human dihydroorotate dehydrogenase (<i>h</i>DHODH), as the fourth and rate-limiting enzyme of the <i>de novo</i> pyrimidine synthesis pathway, is regarded as an attractive target for malignancy therapy. In the present study, a novel series of teriflunomide derivatives were designed, synthesized, and evaluated as <i>h</i>DHODH inhibitors. <b>13t</b> was the optimal compound with promising enzymatic activity (IC<sub>50</sub> = 16.0 nM), potent antiproliferative activity against human lymphoma Raji cells (IC<sub>50</sub> = 7.7 nM), and excellent aqueous solubility (20.1 mg/mL). Mechanistically, <b>13t</b> directly inhibited <i>h</i>DHODH and induced cell cycle S-phase arrest in Raji cells. The acute toxicity assay indicated a favorable safety profile of <b>13t</b>. Notably, <b>13t</b> displayed significant tumor growth inhibition activity with a tumor growth inhibition (TGI) rate of 81.4% at 30 mg/kg in a Raji xenograft model. Together, <b>13t</b> is a promising inhibitor of <i>h</i>DHODH and a preclinical candidate for antitumor therapy, especially for lymphoma.
chemistry, medicinal
What problem does this paper attempt to address?